Published in World J Gastroenterol on November 21, 2010
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol (2012) 1.27
Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma. World J Gastroenterol (2014) 1.26
Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol (2016) 0.82
Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer (2012) 0.79
Hepatitis B virus reactivation in a juvenile rheumatoid arthritis patient under treatment and its successful management: a complicated case. Rheumatol Int (2011) 0.79
Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma. Oncol Lett (2012) 0.77
Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol (2012) 0.75
Treatment of Hepatitis B: A Concise Review. Clin Transl Gastroenterol (2016) 0.75
Update on entecavir in the management of severe forms of Hepatitis B. Hepat Med (2012) 0.75
Use of entecavir in hepatitis B virus reactivation of a patient with non-Hodgkin's lymphoma. World J Gastroenterol (2015) 0.75
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology (2001) 4.81
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology (2009) 2.97
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology (2009) 2.35
Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol (2009) 1.72
Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol (2007) 1.65
Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology (1984) 1.38
High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer (2007) 1.37
Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol (2006) 1.22
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat (2006) 1.17
Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol (2010) 0.98
Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma (2009) 0.94
Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat (2010) 0.92
Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. Z Gastroenterol (2010) 0.90
Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver (1990) 0.83
[A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma]. Gan To Kagaku Ryoho (2009) 0.79
Effective treatment for de novo hepatitis B with nucleotide analogue in patients with hematological malignancies. Am J Hematol (2009) 0.79
Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). Ann Surg (2013) 5.12
A reliable lacZ expression reporter cassette for multipurpose, knockout-first alleles. Genesis (2004) 2.65
Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology (2004) 2.43
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med (2008) 2.18
TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J (2005) 1.90
Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood (2003) 1.84
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res (2006) 1.82
Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology (2010) 1.80
Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment. Gut (2011) 1.75
Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med (2004) 1.74
Mice with targeted disruption of the fatty acid transport protein 4 (Fatp 4, Slc27a4) gene show features of lethal restrictive dermopathy. J Cell Biol (2003) 1.73
Herpes simplex virus encephalitis despite normal cell count in the cerebrospinal fluid. Crit Care Med (2012) 1.67
The diagnosis and treatment of minimal hepatic encephalopathy. Dtsch Arztebl Int (2012) 1.67
Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem (2003) 1.57
Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab (2008) 1.55
Iron stores modulate hepatic hepcidin expression by an HFE-independent pathway. Digestion (2005) 1.55
Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation (2008) 1.55
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res (2006) 1.53
Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4. J Cell Sci (2006) 1.52
An update on swine-origin influenza virus A/H1N1: a review. Virus Genes (2009) 1.52
FAT/CD36-mediated long-chain fatty acid uptake in adipocytes requires plasma membrane rafts. Mol Biol Cell (2004) 1.51
Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation (2009) 1.47
Regulation of transferrin-induced endocytosis by wild-type and C282Y-mutant HFE in transfected HeLa cells. Am J Physiol Cell Physiol (2002) 1.47
Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. J Mol Med (Berl) (2003) 1.46
Iron metabolism and the role of HFE gene polymorphisms in Wilson disease. Liver Int (2011) 1.44
Occult cytomegalovirus cholangitis as a potential cause of cholestatic complications after orthotopic liver transplantation? A study of cytomegalovirus DNA in bile. Liver Transpl (2013) 1.42
One, two, three--p53, p63, p73 and chemosensitivity. Drug Resist Updat (2007) 1.41
The influence of haemodialysis on haemodynamic measurements using transpulmonary thermodilution in patients with septic shock: an observational study. Eur J Anaesthesiol (2013) 1.40
Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med (Berl) (2006) 1.32
Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis (2009) 1.30
Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis (2008) 1.30
Late-onset Wilson's disease. Gastroenterology (2007) 1.30
Enzymatic properties of purified murine fatty acid transport protein 4 and analysis of acyl-CoA synthetase activities in tissues from FATP4 null mice. J Biol Chem (2005) 1.29
Anti-inflammatory effects of phosphatidylcholine. J Biol Chem (2007) 1.29
Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis (2011) 1.27
Association of gp91phox homolog Nox1 with anchorage-independent growth and MAP kinase-activation of transformed human keratinocytes. Oncogene (2003) 1.24
An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg (2006) 1.21
Essential oils of aromatic plants with antibacterial, antifungal, antiviral, and cytotoxic properties--an overview. Forsch Komplementmed (2009) 1.21
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology (2005) 1.21
Safety analysis of endoscopist-directed propofol sedation: a prospective, national multicenter study of 24 441 patients in German outpatient practices. J Gastroenterol Hepatol (2014) 1.20
Caveolin-1 is required for fatty acid translocase (FAT/CD36) localization and function at the plasma membrane of mouse embryonic fibroblasts. Biochim Biophys Acta (2006) 1.19
Acute Zika virus infection after travel to Malaysian Borneo, September 2014. Emerg Infect Dis (2015) 1.18
Screening for antiviral activities of isolated compounds from essential oils. Evid Based Complement Alternat Med (2011) 1.18
Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. Clin Infect Dis (2012) 1.17
The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol (2006) 1.16
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology (2007) 1.15
Long-chain fatty acid uptake into adipocytes depends on lipid raft function. Biochemistry (2004) 1.14
Acyl-CoA synthetases: fatty acid uptake and metabolic channeling. Mol Cell Biochem (2008) 1.13
Translocation of long chain fatty acids across the plasma membrane--lipid rafts and fatty acid transport proteins. Mol Cell Biochem (2006) 1.13
Uptake of long chain fatty acids is regulated by dynamic interaction of FAT/CD36 with cholesterol/sphingolipid enriched microdomains (lipid rafts). BMC Cell Biol (2008) 1.13
Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am J Pathol (2006) 1.13
Primary human hepatocytes--a valuable tool for investigation of apoptosis and hepatitis B virus infection. J Hepatol (2003) 1.11
Cytokine expression during early and late phase of acute Puumala hantavirus infection. BMC Immunol (2011) 1.09
Comparative study on the antiviral activity of selected monoterpenes derived from essential oils. Phytother Res (2010) 1.08
Group B streptococcal beta-hemolysin induces mortality and liver injury in experimental sepsis. J Infect Dis (2002) 1.08
The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology (2007) 1.07
Antiviral effect of aqueous extracts from species of the Lamiaceae family against Herpes simplex virus type 1 and type 2 in vitro. Planta Med (2006) 1.05
Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer (2010) 1.05
Uptake of long-chain fatty acids in HepG2 cells involves caveolae: analysis of a novel pathway. J Lipid Res (2002) 1.03
Immunosuppression and modulation in liver transplantation. Nephrol Dial Transplant (2004) 1.03
Physiologic systemic iron metabolism in mice deficient for duodenal Hfe. Blood (2007) 1.03
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) (2009) 1.03
Alterations in intestinal fatty acid metabolism in inflammatory bowel disease. Biochim Biophys Acta (2006) 1.03
Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol (2013) 1.02
Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph. J Cancer Res Clin Oncol (2012) 1.02
An outbreak of epidemic keratoconjunctivtis in a pediatric unit due to adenovirus type 8. Infect Control Hosp Epidemiol (2003) 1.01
Kinetics of thrombomodulin release and endothelial cell injury by neutrophil-derived proteases and oxygen radicals. Immunology (2002) 1.01
Molecular characterization of a respiratory syncytial virus outbreak in a hematology unit in Heidelberg, Germany. J Clin Microbiol (2012) 1.00
Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol (2006) 1.00
Are heat stroke and physical exhaustion underestimated causes of acute hepatic failure? World J Gastroenterol (2007) 1.00
Reduction of needlestick injuries in healthcare personnel at a university hospital using safety devices. J Occup Med Toxicol (2013) 1.00
Expression of reelin in hepatic stellate cells and during hepatic tissue repair: a novel marker for the differentiation of HSC from other liver myofibroblasts. J Hepatol (2002) 0.99
Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer. Oncol Rep (2007) 0.99
Disturbed epidermal structure in mice with temporally controlled fatp4 deficiency. J Invest Dermatol (2005) 0.99
Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem Biophys Res Commun (2010) 0.99
IGF-I induces DNA synthesis and apoptosis in rat liver hepatic stellate cells (HSC) but DNA synthesis and proliferation in rat liver myofibroblasts (rMF). Lab Invest (2004) 0.98
Polysaccharides from Sargassum tenerrimum: structural features, chemical modification and anti-viral activity. Phytochemistry (2010) 0.98
A constitutive NADPH oxidase-like system containing gp91phox homologs in human keratinocytes. J Invest Dermatol (2004) 0.98
Analysis of the human homologue of the canine copper toxicosis gene MURR1 in Wilson disease patients. J Mol Med (Berl) (2004) 0.98
Rat liver myofibroblasts and hepatic stellate cells differ in CD95-mediated apoptosis and response to TNF-alpha. Am J Physiol Gastrointest Liver Physiol (2002) 0.98
Relationships and distinctions in iron-regulatory networks responding to interrelated signals. Blood (2002) 0.98
TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol (2009) 0.98
Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. BMC Gastroenterol (2009) 0.97
New concepts of cellular fatty acid uptake: role of fatty acid transport proteins and of caveolae. Proc Nutr Soc (2004) 0.97
Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis. Inflamm Bowel Dis (2006) 0.97
Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins. J Cell Biochem (2011) 0.97
Bacteriobilia and fungibilia are associated with outcome in patients with endoscopic treatment of biliary complications after liver transplantation. Endoscopy (2013) 0.96
Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells. Int J Med Sci (2011) 0.96
A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology (2008) 0.96
Mechanism of herpes simplex virus type 2 suppression by propolis extracts. Phytomedicine (2009) 0.95
Early treatment of imported falciparum malaria in the intermediate and intensive care unit setting: an 8-year single-center retrospective study. Crit Care (2008) 0.95
Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology (2012) 0.95
Iron overload in adult Hfe-deficient mice independent of changes in the steady-state expression of the duodenal iron transporters DMT1 and Ireg1/ferroportin. J Mol Med (Berl) (2003) 0.95
Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology (2009) 0.94